YB1-mRNA
/ HKND YB1 Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
January 27, 2026
Y box binding protein 1 mediated modulation of chromosomal instability in cancer
(LCC 2026)
- "Our pan-cancer dataset analysis revealed a strong association between high YB-1 mRNA expression, increased genomic instability, and reduced disease-free survival. To explore this, we engineered H1299 lung cancer cells with tetracycline-inducible YB-1 expression...We are currently evaluating the functional consequences of prolonged YB-1 overexpression. Collectively, our data identifies, for the first time, a direct mechanistic link between YB-1 overexpression and CIN, establishing YB-1 as a key driver of tumour evolution and a promising therapeutic target."
Lung Cancer • Oncology • Solid Tumor • YBX1
November 04, 2025
Immunohistochemical analysis of YB-1 expression in the developing mouse eye.
(PubMed, Eur J Histochem)
- "YB-1 mRNA could be detected by RT-PCR and sequencing the PCR product in retinal tissue of adult mice...Expression of the YB-1 protein was detected in all retinal cells, as well as in the corneal and lens epithelial cells, throughout all stages of eye development examined. These findings suggest that YB-1 could have a significant role in the eye, potentially related to development and differentiation."
Journal • Preclinical • Oncology
August 31, 2025
Autoregulation of YB-1 Synthesis in Cells.
(PubMed, Biochemistry (Mosc))
- "Experiments with reporter constructs showed that both UTRs of the YB-1 mRNA are involved in autoregulation, thus resolving the contradiction in the literature. These results highlight a sophisticated mechanism for controlling YB-1 levels, which requires both 5' and 3' UTRs of the YB-1 mRNA, and confirm their role in fine-tuning YB-1 synthesis."
Journal • YBX1
August 21, 2025
Targeting YBX1: A novel therapeutic strategy for gastric cancer through regulation of cellular senescence and mTOR signaling.
(PubMed, Tissue Cell)
- "YBX1 mRNA and protein levels were significantly higher in GC tissues than in adjacent normal tissues (P < 0.001), and high expression was associated with reduced overall survival (P < 0.05)...Thus, this study underscores YBX1 as a pivotal regulator of GC cell proliferation, senescence, and survival, offering a promising avenue for targeted therapies. By leveraging YBX1 inhibition, this work lays a foundation for developing precision medicine approaches in GC treatment."
Journal • Gastric Cancer • Oncology • Solid Tumor • EIF4EBP1 • YBX1
April 19, 2025
Oncolytic virotherapy provides a potent therapy option for squamous bladder cancer.
(PubMed, Sci Rep)
- "Increased YB-1-mRNA expression was detected in basal/squamous subtype in TCGA BLCA cohort compared to urothelial and luminal BLCA and correlated with patient outcomes...In a novel in ovo xenograft model, XVir-N-31 impaired growth of xenografts of patient-derived ex vivo cell lines (p-SCC, p-UC) with growth suppression rates of 39-49%. We provide preclinical evidence ex vivo and in ovo for high efficacy of XVir-N-31 based oncolytic virotherapy as novel SCC therapy."
Journal • Bladder Cancer • Genito-urinary Cancer • Infectious Disease • Oncology • Solid Tumor • Squamous Cell Carcinoma • Urothelial Cancer • YBX1
September 20, 2024
Y-box binding protein 1/cyclin A1 axis specifically promotes cell cycle progression at G2/M phase in ovarian cancer.
(PubMed, Sci Rep)
- "YBX1 mRNA levels were significantly correlated with cyclin A1 mRNA levels in patients with high-grade serous carcinoma. Augmented YBX1 expression plays a key role in tumor growth promotion in ovarian cancer in its close association with cyclin A1."
Journal • Oncology • Ovarian Cancer • Solid Tumor • CCNA1 • YBX1
1 to 6
Of
6
Go to page
1